Pfizer's new obesity combo pill enters human testing
NCT ID NCT06924320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two experimental drugs, MET233 and MET097, can help adults with obesity or overweight lose weight, including those with type 2 diabetes. About 381 participants will receive either the drug combination or a placebo to check safety and how well the body processes the drugs. The goal is to find a new treatment option for weight management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Altasciences Clinical Los Angeles, Inc.
RECRUITINGCypress, California, 90630, United States